Eli Lilly to discontinue four unprofitable insulin drugs

Eli Lilly will remove four insulin drugs with low or falling sales from the U.S. market, including its remaining animal-based insulins. Biosynthetic insulins began replacing animal insulins in 1983. Two percent of the 3.5 million insulin users in the U.S. depend on these products and will have until the end of the year to find replacements. The discontinued products make up a small percentage of the company's total insulin sales of more than $2 billion a year.

View Full Article in:

Indianapolis Star (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR